p53 gene therapy - MultiVirAlternative Names: Ad-p53 - MultiVir; Adenoviral p53 - MultiVir
Latest Information Update: 01 Aug 2016
At a glance
- Originator MultiVir
- Class Antineoplastics; Gene therapies
- Mechanism of Action Apoptosis stimulants; Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Liver metastases
Most Recent Events
- 01 Jun 2016 MultiVir initiates a phase I trial for Liver metastases (Combination therapy, Second-line therapy or greater) in USA (NCT02842125)
- 14 Feb 2014 Phase-I clinical trials in Colorectal cancer (combination therapy, metastatic disease) in USA before February 2014 (unspecified route)